India's Cipla top loser on Nifty 50 after brokerages cut ratings on earnings risk

Cipla

16/01/2026 05:24

** Drugmaker Cipla's CIPL.NS stock falls as much as 4.7% to 1,367.20 rupees, lowest level since April 2025

** Last down 2.4%, top loser on Nifty 50 .NSEI, which is up 0.77%

** Tumour drug Lanreotide supply hit after partner Pharmathen's production pause; drug is major rev source for CIPL in U.S.

** Nuvama downgrades to "reduce" from "hold", cuts PT to 1,360 rupees from 1,715 rupees; says pause brings uncertainty for FY27E

** BofA Securities cuts PT to 1,420 rupees from 1,500 rupees; says co's near-term earnings, news flow could weigh on stock

** Morgan Stanley says pause creates U.S. revenue overhang; stock to underperform over next 30 days

** CIPL rated "buy" on avg by 36 analysts, median PT 1,675 rupees - LSEG data

(Reporting by Brijesh Patel in Bengaluru)

((Brijesh.Patel1@thomsonreuters.com; Ph no. +91 9590227221;))